+1-206-701-6702
+44-020-8133-4027
+81-50-5539-1737
+91-848-285-0837
India Immune-Oncology Drugs Market – Insights
Immuno-oncology products come under biological therapeutic products. Immuno-oncology drugs are primarily used in therapeutic applications for treatment of various types of cancer such as lung cancer, breast cancer, colon cancer, and cervical cancer. Major players involved in the Indian immuno-oncology drugs market are focusing on research and development of new technologies and products. Several biopharmaceuticals and research organizations have been indigenously developing biologics in cancer treatment. For instance, researchers from Tata Centre for Technology and Design, IIT Bombay are currently working on developing indigenous CAR (chimeric antigen receptor) T-cell therapy, affordable for cancer patients in India.
India immune-oncology drugs market size was valued at US$ 172.8 million in 2018 and is expected to witness a CAGR of 13.1% over the forecast period (2018 – 2026).
India Immune-Oncology Drugs Market Share (%) Analysis, By Drug Type, 2018
Source: Coherent Market Insights Analysis (2019)
Increasing Incidences of Cancer Cases and Introduction of Novel Immuno-Oncology Therapies is expected to Drive Growth of the India Immune-Oncology Drugs Market
Rising incidences of cancer in India is expected to boost the immuno-oncology drugs market during the forecast period. For instance, according to Indian Council of Medical Research (ICMR) - National Institute of Cancer Prevention and Research (NICPR), incidence of breast cancer is 25.8 per 100,000 women in 2018 and is expected to reach 35 per 100,000 women in 2026.
The immune-oncology drugs market is expected to generate a high revenue, owing to increasing introduction of new novel therapies for treatment of cancer with improved therapeutic outcomes that have led to increasing success rates against cancer. Novel immune therapies can restore the ability of immune system to identify and eliminate cancer cells, which is generally suppressed during course of cancer progression. Such immuno-oncology based therapies can be tailored to attack or block particular targets. For instance, Iplimumab, a human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is available.
Cancer vaccines have also been developed such as Sipuleucel-T, Gardasil, and Cervarix. These vaccines either work as preventive vaccines or therapeutic vaccines. Adoptive cell transfer therapy is a new therapy emerging in the immuno-oncology such as CAR-T Cell Therapy, under which Kymriah and Yescarta are available.
Furthermore, organizations focusing on specific immune regulatory checkpoints such as programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1) such as Nivolumab, Atezolimumab, and Pembrolizumab are being used for cell lung cancer. Monoclonal antibodies have been further developed into conjugated monoclonal antibodies, which are combined with other agents such as radiolabeled antibodies and chemo labeled antibodies.
India Immune-Oncology Drugs Market - Restraints
Major restraining factors for India immune-oncology drugs market include inadequate delivery of affordable and equitable cancer care drugs in India, which hampers the India immune-oncology drugs market. For instance, according to the data published in Lancet Journal in 2014, public expenditure on cancer in India remains below US$ 10 per person (compared to over US$ 100 per person in high-income or developed countries) and overall public expenditure on healthcare is still only slightly above 1% of the gross domestic product. According to the same source, out-of-pocket payments, which account for over three-quarter of cancer expenditures in India are one of the greatest threats to patients and families. Moreover, higher effectiveness of cancer drugs and comparatively less availability of better alternative results restricts key players to drive down cost of cancer drugs.
India Immune-Oncology Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
Source: Coherent Market Insights Analysis (2019)
India Immune-Oncology Drugs Market - Competitive Landscape
Key players operating in the India Immune-Oncology Drugs market include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories Ltd., Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology Company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited.
Immuno-Oncology refers to the use of body’s natural defenses to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. Immuno-oncology drugs facilitates long-term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology drugs works against a wide variety of cancers, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, and other therapies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.
Market Dynamics
Increasing prevalence of cancer in India is expected to drive India Immuno-Oncology Drugs market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.
However, factors such as high-cost associated with immuno-oncology therapies makes it unaffordable for population in the low and middle-income class, to opt for these therapies, thus restraining growth of the market. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg. Moreover, according to the World Health Organization (WHO), in February 2018, around 70% of deaths from cancer occur in low and middle-income countries. This can be attributed to high-prices of oncology therapies, which cannot be afforded by patients with low incomes.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Contact Us
